Partner Company releases positive clinical results

Amphion Innovations plc

 ("Amphion" or "the Company")

Amphion Partner Company, Motif Bio, Announces Positive Topline Results for iclaprim in the REVIVE-2 Phase 3 Study

· Iclaprim met the primary endpoint

· Iclaprim was well tolerated in the study

· NDA submission expected in the first quarter of 2018

Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, comments on Partner Company Motif Bio plc ("Motif", AIM: MTFB, NASDAQ: MTFB) following positive topline results from its REVIVE-2 trial, a global Phase 3 clinical trial evaluating Motif's lead investigational drug candidate iclaprim in patients with acute bacterial skin and skin structure infections (ABSSSI), as announced 4 October 2017.

Amphion owns 14.1% of Motif Bio's issued share capital.

Richard Morgan, CEO of Amphion Innovations commented: "We are pleased that Motif Bio's lead antibiotic, iclaprim, has now successfully completed both of its Phase III trials. Yesterday, Motif Bio announced the topline data for REVIVE-2, the second of the two trials, which showed that iclaprim achieved the primary endpoint of non-inferiority compared to vancomycin, the current standard of care, at the early time point (ETP), and also achieved non-inferiority at the test of cure endpoint, 7 to 14 days after study drug discontinuation. Combined with the positive topline data for REVIVE-1, as announced 18 April 2017, Motif Bio is on track to submit a New Drug Application to the US FDA for iclaprim in the first quarter of 2018. Amphion owns 14.1% of Motif Bio, and we continue to believe that Motif Bio is not fully valued compared to other comparable antibiotic companies at the same stage of development."

For further information please contact:

About Amphion Innovations plc

Amphion Innovations is a developer of medical, life science and technology businesses.

We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number which grows rapidly each year.

On the web: www.amphionplc.com